Welcome to our dedicated page for Quantum-Si Incorporated SEC filings (Ticker: QSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Quantum-Si Incorporated (Nasdaq: QSI), a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. Here, investors can review how Quantum-Si reports its financial performance, capital structure, and material corporate events in official regulatory documents.
Quantum-Si’s periodic reports, such as its quarterly results furnished via Form 8-K, provide detail on product and service revenue, cost of revenue, research and development spending, selling, general and administrative expenses, and items like lease termination or legal settlement expenses. These filings also include condensed consolidated balance sheets and statements of operations, along with non-GAAP metrics such as adjusted total operating expenses and adjusted EBITDA, together with reconciliations to GAAP measures.
Capital markets and financing activities are documented in Forms 8-K and related registration statements. Examples include a registered direct offering of Class A common stock and pre-funded warrants, an at-the-market Sales Agreement for Class A common stock, and the termination of a prior equity distribution agreement. Filings describe intended uses of proceeds, such as funding the Proteus platform development, commercialization, manufacturing development, research and development, and general corporate purposes.
Other material agreements and corporate actions, including lease terminations, settlement and mutual release agreements, and inducement equity awards under the 2023 Inducement Equity Incentive Plan, are also reported in Quantum-Si’s SEC filings. Stock Titan’s interface adds AI-powered summaries that highlight key terms, financial impacts, and timelines from these documents, helping readers quickly understand complex agreements, capital raises, and operating decisions without reading every line of each filing.
Quantum-Si Incorporated reported Q1 2026 results showing sharply lower revenue and continued investment in proteomics R&D. Total revenue was $258 thousand, down 69.4% from $842 thousand a year earlier, mainly because customers delayed instrument and consumable purchases ahead of the anticipated Proteus platform launch by the end of 2026.
Gross profit fell to $74 thousand and gross margin declined to 28.7% from 57.7% as product mix and lower volumes weighed on profitability. Research and development expenses rose 5.6% to $14.5 million, reflecting higher lab supplies, payroll and outsourced work to advance Proteus, while selling, general and administrative costs fell 18.9% to $9.6 million due to lower legal, payroll and marketing spend.
The company recorded a net loss of $21.7 million, compared with a $19.2 million net loss in Q1 2025, and used $25.6 million in operating cash. As of March 31, 2026, Quantum-Si held $190.4 million of cash, cash equivalents and marketable securities, which management believes is sufficient to fund planned operations for at least the next twelve months.
Quantum-Si Incorporated reported first quarter 2026 results and updated its 2026 outlook. Revenue for the quarter was $258,000, generating gross profit of $74,000 and a gross margin of 29%. Net loss was $21.7 million, while adjusted EBITDA was negative $20.1 million.
Adjusted total operating expenses were $21.4 million, down from $22.9 million a year earlier as the company managed selling, general and administrative costs while increasing research and development for its Proteus platform. Cash, cash equivalents and marketable securities totaled $190.4 million as of March 31, 2026, which the company anticipates will fund operations into the second quarter of 2028.
For full-year 2026, Quantum-Si reiterated guidance of approximately $1.0 million in revenue, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less, reflecting a transition year focused on preparing the Proteus single-molecule protein sequencing system for an anticipated commercial launch at the end of 2026.
Quantum-Si Inc Chief Financial Officer Jeffry R. Keyes reported mandatory tax-related share sales. He sold 37,382 shares of Class A Common Stock on April 20, 2026 at a weighted average price of $1.0064 per share and 37,381 shares on April 21, 2026 at a weighted average price of $0.9950 per share.
According to the footnotes, both transactions were executed under a mandatory Quantum-Si sell-to-cover provision to satisfy federal, state and local withholding taxes associated with vesting restricted stock units, and he could not alter this provision. After these transactions, he directly owns 1,732,582 Class A shares.
Quantum-Si Inc President & CEO Jeffrey Alan Hawkins reported two open-market sales of Class A Common Stock tied to tax withholding. He sold 83,712 shares on April 20, 2026 at a weighted average price of $1.0064 per share and another 83,712 shares on April 21, 2026 at a weighted average price of $0.9950 per share. According to the disclosure, these transactions were executed under a mandatory sell-to-cover provision to satisfy federal, state and local withholding taxes triggered by the vesting of previously granted restricted stock units. After these sales, Hawkins directly owned 3,692,423 shares of Quantum-Si Class A Common Stock.
Quantum-Si Incorporated notice of proposed sale of 187,500 Class A Common Stock linked to Restricted Stock Unit Vesting on 04/22/2026. The filing also records 8,655 shares sold on 03/20/2026 by Morgan Stanley Smith Barney LLC as shown. The securities are described as equity compensation for services rendered.
Quantum-Si Incorporated disclosed a Form 144 notice related to Class A Common Stock tied to a Restricted Stock Unit vesting event. The filing lists 416,667 shares associated with the RSU vesting dated 04/22/2026 and records a prior sale of 23,777 shares on 03/20/2026. The broker listed is Morgan Stanley Smith Barney LLC.
Quantum-Si Incorporated has called a fully virtual 2026 annual meeting for 1:00 p.m. Eastern on May 15, 2026. Stockholders will vote on electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving a non-binding advisory say-on-pay for named executive officers.
The company has a dual-class structure with 196,431,273 Class A shares and 19,937,500 Class B shares outstanding as of March 20, 2026, with Class B carrying 20 votes per share. Founder Jonathan M. Rothberg, Ph.D. beneficially owns all Class B shares and about 69.33% of total voting power, effectively controlling the outcome of all proposals.
Quantum-Si Inc Chief Financial Officer Jeffry R. Keyes reported routine tax-related stock sales. He sold a total of 8,655 shares of Class A Common Stock in open-market transactions on March 20 and March 23 at weighted average prices around $0.83 per share.
According to the footnotes, these sales were made under a mandatory Quantum-Si sell-to-cover provision to satisfy federal, state and local withholding taxes tied to the vesting of previously granted restricted stock units. After these transactions, he continued to hold 1,807,345 shares directly.
Quantum-Si Inc’s General Counsel and Corporate Secretary, Christian LaPointe, reported two open-market sales totaling 11,959 shares of Class A Common Stock. According to the disclosure, these sales were mandatory sell-to-cover transactions for federal, state, and local tax withholding on vested restricted stock units. LaPointe continues to hold 1,198,017 shares directly after the transactions.